Acelyrin, Inc.

NasdaqGS SLRN

Acelyrin, Inc. EBITDA Margin for the Trailing 12 Months (TTM) ending September 30, 2024: -198,146.99%

Acelyrin, Inc. EBITDA Margin is -198,146.99% for the Trailing 12 Months (TTM) ending September 30, 2024. EBITDA Ratio is the proportion of Earnings Before Interest, Taxes, Depreciation, and Amortization to total revenue, assessing a company's operational profitability before non-operating expenses and non-cash charges.
Key data
Date EBITDA Margin EBIT Margin Depreciation and Amortization EBIT
Market news
SV Wall Street
NasdaqGS: SLRN

Acelyrin, Inc.

CEO Ms. Mina Kim J.D.
IPO Date May 4, 2023
Location United States
Headquarters 4149 Liberty Canyon Road
Employees 135
Sector Healthcare
Industries
Biotechnology 3D Printing Clinical Trials Cosmetics Eyewear Pharmaceuticals Vaccines
Description

Acelyrin, Inc., a clinical biopharma company, focuses on identifying, acquiring, and accelerating the development and commercialization of transformative medicines. The company's lead product candidate is izokibep, a small protein therapeutic designed to inhibit IL-17A with high potency, which is in Phase 3 clinical trials for use in the treatment of Hidradenitis Suppurativa, Psoriatic Arthritis, and uveitis, as well as in Phase 2 clinical trials for use in the treatment of Axial Spondyloarthritis. It is also developing lonigutamab, a humanized immunoglobulin G1 (IgG1) monoclonal antibody against insulin-like growth factor 1 receptor, which is in Phase 1 clinical trials for use in the treatment of thyroid eye disease; and SLRN-517, a fully human IgG1 monoclonal antibody targeting c-KIT, which is in preclinical stage for use in the treatment of chronic urticaria. The company was incorporated in 2020 and is headquartered in Agoura Hills, California.

StockViz Staff

February 4, 2025

Any question? Send us an email